“In April 2014, Francis Collins stood before a US Congressional committee and touted the creation of an “unprecedented public–private effort” that would use “cutting-edge scientific approaches to sift through a long list of potential therapeutic targets and biomarkers” and ultimately “treat and cure disease faster”.
“Five years and hundreds of millions of dollars later, the Accelerating Medicines Partnership (AMP) is delivering on that promise, says Collins. Most notably, AMP has created new technology standards for studying the diseased cells responsible for lupus and rheumatoid arthritis (RA), and has produced publicly available resources for analysing the genetic basis of Alzheimer disease and type 2 diabetes…” Read the full article here.
Source: Massive NIH–industry project opens portals to target validation – By Elie Dolgin, February 27, 2019. Nature.com.
